You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 18, 2024

Lopinavir; ritonavir - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for lopinavir; ritonavir and what is the scope of patent protection?

Lopinavir; ritonavir is the generic ingredient in two branded drugs marketed by Abbvie, Lannett Co Inc, Hetero Labs Ltd Iii, Laurus, and Mylan Labs Ltd, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Five suppliers are listed for this compound. There are four tentative approvals for this compound.

Recent Clinical Trials for lopinavir; ritonavir

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of WashingtonPhase 1
University of Wisconsin, MadisonPhase 1
Wisconsin Partnership ProgramPhase 1

See all lopinavir; ritonavir clinical trials

Generic filers with tentative approvals for LOPINAVIR; RITONAVIR
Applicant Application No. Strength Dosage Form
⤷  Try a Trial⤷  Try a Trial200MG; 50MGTABLET; ORAL
⤷  Try a Trial⤷  Try a Trial200MG; 50MGTABLET; ORAL
⤷  Try a Trial⤷  Try a Trial100MG; 25MGTABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for LOPINAVIR; RITONAVIR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
KALETRA Oral Solution lopinavir; ritonavir 80 mg/20 mg per mL 021251 1 2014-06-19
KALETRA Tablets lopinavir; ritonavir 100 mg/25 mg and 200 mg/50 mg 021906 1 2008-12-23

US Patents and Regulatory Information for lopinavir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Labs Ltd LOPINAVIR AND RITONAVIR lopinavir; ritonavir TABLET;ORAL 079074-002 Feb 7, 2024 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-002 Nov 9, 2007 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Laurus LOPINAVIR AND RITONAVIR lopinavir; ritonavir TABLET;ORAL 213857-001 Mar 21, 2022 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for lopinavir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-002 Nov 9, 2007 ⤷  Try a Trial ⤷  Try a Trial
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-002 Nov 9, 2007 ⤷  Try a Trial ⤷  Try a Trial
Abbvie KALETRA lopinavir; ritonavir CAPSULE;ORAL 021226-001 Sep 15, 2000 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for lopinavir; ritonavir

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Mylan Pharmaceuticals Limited Lopinavir/Ritonavir Mylan lopinavir, ritonavir EMEA/H/C/004025
Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.The choice of lopinavir/ritonavir to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
Authorised yes no no 2016-01-14
AbbVie Deutschland GmbH Co. KG Kaletra lopinavir, ritonavir EMEA/H/C/000368
Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
Authorised no no no 2001-03-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.